<DOC>
	<DOCNO>NCT01878669</DOCNO>
	<brief_summary>The aim study evaluate effect N-acetyl cysteine periprocedural myocardial infarction major cardiac cerebral event patient undergo percutaneous coronary intervention moderate high risk contrast induce nephropathy .</brief_summary>
	<brief_title>Effects N-acetyl Cysteine During Percutaneous Coronary Intervention</brief_title>
	<detailed_description />
	<mesh_term>Coronary Artery Disease</mesh_term>
	<mesh_term>Myocardial Ischemia</mesh_term>
	<mesh_term>Coronary Disease</mesh_term>
	<mesh_term>Acetylcysteine</mesh_term>
	<mesh_term>N-monoacetylcystine</mesh_term>
	<criteria>Patients &gt; 18 year old undergoing percutaneous coronary intervention moderate high risk contrast induce nephropathy ( Mehran Score â‰¥ 5 ) Primary percutaneous coronary intervention Low risk contrast induce nephropathy ( Mehran Score &lt; 5 ) Use nephrotoxic agent ( NSAIDs , aminoglycosides , recent contrast injection ... ) Infection Pregnancy , Lactation Renal failure require dialysis Hepatic failure History allergy NAC History Asthma Chronic nitrate usage Malignancy Use corticosteroid Leukocytosis , Thrombocytosis , Anemia Blood pressure &gt; 180/100mmHg despite antihypertensive therapy</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>85 Years</maximum_age>
	<verification_date>January 2017</verification_date>
	<keyword>n-acetyl cysteine</keyword>
	<keyword>percutaneous coronary intervention</keyword>
</DOC>